Latest news

Adalvo today announced that it has entered into partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex...

Adalvo is delighted to announce successful Fed and Fast Pivotal BE outcome of its Solifenacin + Tamsulosin development which demonstrates Adalvo's ability to continuously offer first-to-market opportunities to its valued...

Adalvo today announces that it has submitted filings for generic dossier applications with the European Medicines Agency, seeking approval to market an Icatibant pre-filled syringe. Based on available information, Adalvo...

New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.

Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with...

Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the...

We are living through a very challenging time. The Coronavirus spread is causing changes in everyday life and we are constantly monitoring the situation here at Adalvo

Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets.

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for...

This February the Adalvo team got together in Zurich, Switzerland for a Kick Off meeting.

Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries....